Zenshine Pharmaceuticals (Nanjing) Group (ZPN HK): Synthetic Expert Call Transcript (29 Aug 2026)
No Superiority Over Xofluza: While Zenshine’s core product, sebaloxavir marboxil (ZX-7101A), boasts a 37.4% placebo-adjusted reduction in Time to...
105 Views
IPO Databook: Zenshine Pharmaceuticals (Nanjing) Group (HK) - Aug 2026
Zenshine Pharmaceuticals, founded in 2018, is a commercial-stage biopharmaceutical company developing therapeutics for viral infectious diseases,...
101 Views
Primer: Zenshine Pharmaceuticals (Nanjing) Group (ZPN HK) - Aug 2026
Zenshine Pharmaceuticals is a commercial-stage biopharmaceutical company with a primary focus on antiviral and oncology therapies, poised for...
108 Views
Pre-IPO Zenshine Pharmaceuticals (Nanjing) Group - The Core Product Faces Significant Challenges
Zenshine faces intense competition in the influenza drug market, with uncertain commercialization outlook for sebaloxavir marboxil, which...
122 Views
Zenshine (征祥医药) Pre-IPO: Differentiation Overstated in a Crowded PA CEN Class
China biotech Zenshine seeks $100M through Hong Kong listing with CICC as sole sponsor. We look at its product ZX-7101A, pre-IPO investors and...
198 Views